vs

Side-by-side financial comparison of Legacy Housing Corp (LEGH) and TriSalus Life Sciences, Inc. (TLSI). Click either name above to swap in a different company.

Legacy Housing Corp is the larger business by last-quarter revenue ($25.5M vs $13.2M, roughly 1.9× TriSalus Life Sciences, Inc.). Legacy Housing Corp runs the higher net margin — 32.2% vs -73.9%, a 106.0% gap on every dollar of revenue. On growth, TriSalus Life Sciences, Inc. posted the faster year-over-year revenue change (59.8% vs -30.6%). Legacy Housing Corp produced more free cash flow last quarter ($15.7M vs $-2.5M). Over the past eight quarters, TriSalus Life Sciences, Inc.'s revenue compounded faster (43.0% CAGR vs -9.1%).

Legacy Housing Corp is a prominent U.S.-based manufacturer of affordable manufactured homes, tiny homes, and accessory dwelling units. It mainly caters to low- and middle-income consumers across North America, providing customizable residential solutions, supporting construction materials, and after-sales services for individual and community development clients.

TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on advancing immuno-oncology and interventional oncology solutions. It develops proprietary targeted drug delivery technologies designed to improve treatment efficacy for patients with liver, pancreatic and other hard-to-treat solid tumors, primarily operating in North American markets via partnerships with clinical care and research institutions.

LEGH vs TLSI — Head-to-Head

Bigger by revenue
LEGH
LEGH
1.9× larger
LEGH
$25.5M
$13.2M
TLSI
Growing faster (revenue YoY)
TLSI
TLSI
+90.4% gap
TLSI
59.8%
-30.6%
LEGH
Higher net margin
LEGH
LEGH
106.0% more per $
LEGH
32.2%
-73.9%
TLSI
More free cash flow
LEGH
LEGH
$18.2M more FCF
LEGH
$15.7M
$-2.5M
TLSI
Faster 2-yr revenue CAGR
TLSI
TLSI
Annualised
TLSI
43.0%
-9.1%
LEGH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LEGH
LEGH
TLSI
TLSI
Revenue
$25.5M
$13.2M
Net Profit
$8.2M
$-9.8M
Gross Margin
26.4%
86.7%
Operating Margin
40.4%
-24.8%
Net Margin
32.2%
-73.9%
Revenue YoY
-30.6%
59.8%
Net Profit YoY
-43.5%
3.5%
EPS (diluted)
$0.38
$-0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LEGH
LEGH
TLSI
TLSI
Q4 25
$25.5M
$13.2M
Q3 25
$28.8M
$11.6M
Q2 25
$38.4M
$11.2M
Q1 25
$24.3M
$9.2M
Q4 24
$36.7M
$8.3M
Q3 24
$30.2M
$7.3M
Q2 24
$31.7M
$7.4M
Q1 24
$30.8M
$6.5M
Net Profit
LEGH
LEGH
TLSI
TLSI
Q4 25
$8.2M
$-9.8M
Q3 25
$8.6M
$-10.8M
Q2 25
$14.7M
$-8.3M
Q1 25
$10.3M
$-10.4M
Q4 24
$14.5M
$-10.1M
Q3 24
$15.8M
$-2.4M
Q2 24
$16.2M
$-4.3M
Q1 24
$15.1M
$-13.2M
Gross Margin
LEGH
LEGH
TLSI
TLSI
Q4 25
26.4%
86.7%
Q3 25
20.2%
83.5%
Q2 25
32.4%
83.9%
Q1 25
29.2%
83.7%
Q4 24
27.3%
85.3%
Q3 24
29.2%
86.3%
Q2 24
31.9%
87.6%
Q1 24
33.6%
85.0%
Operating Margin
LEGH
LEGH
TLSI
TLSI
Q4 25
40.4%
-24.8%
Q3 25
33.7%
-77.9%
Q2 25
43.8%
-65.4%
Q1 25
47.7%
-79.9%
Q4 24
42.3%
-91.8%
Q3 24
50.8%
-118.9%
Q2 24
50.6%
-111.0%
Q1 24
54.3%
-180.8%
Net Margin
LEGH
LEGH
TLSI
TLSI
Q4 25
32.2%
-73.9%
Q3 25
30.0%
-93.5%
Q2 25
38.3%
-73.9%
Q1 25
42.3%
-113.2%
Q4 24
39.5%
-122.4%
Q3 24
52.4%
-32.6%
Q2 24
51.1%
-58.8%
Q1 24
49.1%
-204.5%
EPS (diluted)
LEGH
LEGH
TLSI
TLSI
Q4 25
$0.38
$-0.22
Q3 25
$0.35
$-0.96
Q2 25
$0.60
$-0.27
Q1 25
$0.41
$-0.39
Q4 24
$0.59
$-0.38
Q3 24
$0.64
$-0.12
Q2 24
$0.65
$-0.21
Q1 24
$0.60
$-0.60

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LEGH
LEGH
TLSI
TLSI
Cash + ST InvestmentsLiquidity on hand
$8.5M
$20.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$528.6M
$-33.9M
Total Assets
$580.3M
$35.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LEGH
LEGH
TLSI
TLSI
Q4 25
$8.5M
$20.4M
Q3 25
$13.6M
$22.7M
Q2 25
$2.6M
$26.5M
Q1 25
$3.4M
$13.0M
Q4 24
$1.1M
$8.5M
Q3 24
$570.0K
$11.3M
Q2 24
$60.0K
$16.5M
Q1 24
$621.0K
$4.0M
Stockholders' Equity
LEGH
LEGH
TLSI
TLSI
Q4 25
$528.6M
$-33.9M
Q3 25
$521.6M
$-26.7M
Q2 25
$512.8M
$-19.4M
Q1 25
$503.7M
$-34.4M
Q4 24
$494.0M
$-25.9M
Q3 24
$479.3M
$-20.4M
Q2 24
$463.2M
$-25.3M
Q1 24
$450.4M
$-36.0M
Total Assets
LEGH
LEGH
TLSI
TLSI
Q4 25
$580.3M
$35.3M
Q3 25
$557.9M
$36.5M
Q2 25
$552.0M
$41.3M
Q1 25
$544.6M
$28.6M
Q4 24
$534.2M
$24.0M
Q3 24
$521.4M
$27.5M
Q2 24
$514.9M
$32.4M
Q1 24
$510.0M
$17.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LEGH
LEGH
TLSI
TLSI
Operating Cash FlowLast quarter
$19.0M
$-2.5M
Free Cash FlowOCF − Capex
$15.7M
$-2.5M
FCF MarginFCF / Revenue
61.6%
-19.1%
Capex IntensityCapex / Revenue
13.1%
0.3%
Cash ConversionOCF / Net Profit
2.32×
TTM Free Cash FlowTrailing 4 quarters
$28.2M
$-19.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LEGH
LEGH
TLSI
TLSI
Q4 25
$19.0M
$-2.5M
Q3 25
$7.2M
$-3.7M
Q2 25
$6.1M
$-7.3M
Q1 25
$4.9M
$-4.5M
Q4 24
$7.9M
$-5.7M
Q3 24
$13.8M
$-10.8M
Q2 24
$3.5M
$-13.4M
Q1 24
$10.8M
$-10.9M
Free Cash Flow
LEGH
LEGH
TLSI
TLSI
Q4 25
$15.7M
$-2.5M
Q3 25
$5.1M
$-3.9M
Q2 25
$3.7M
$-7.4M
Q1 25
$3.6M
$-5.3M
Q4 24
$6.0M
$-5.8M
Q3 24
$9.1M
$-11.0M
Q2 24
$1.7M
$-13.5M
Q1 24
$9.9M
$-10.9M
FCF Margin
LEGH
LEGH
TLSI
TLSI
Q4 25
61.6%
-19.1%
Q3 25
17.8%
-33.9%
Q2 25
9.6%
-66.1%
Q1 25
15.0%
-57.3%
Q4 24
16.4%
-69.7%
Q3 24
30.2%
-149.9%
Q2 24
5.4%
-183.1%
Q1 24
32.2%
-169.3%
Capex Intensity
LEGH
LEGH
TLSI
TLSI
Q4 25
13.1%
0.3%
Q3 25
7.1%
1.9%
Q2 25
6.2%
0.8%
Q1 25
5.2%
8.2%
Q4 24
5.1%
0.6%
Q3 24
15.6%
2.3%
Q2 24
5.5%
0.8%
Q1 24
2.8%
1.0%
Cash Conversion
LEGH
LEGH
TLSI
TLSI
Q4 25
2.32×
Q3 25
0.83×
Q2 25
0.41×
Q1 25
0.48×
Q4 24
0.54×
Q3 24
0.88×
Q2 24
0.21×
Q1 24
0.71×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LEGH
LEGH

Commercial Sales$8.6M34%
Retail Store Sales$6.0M24%
Inventory Finance Sales$5.0M20%
Direct Sales$4.4M17%
Other$1.5M6%

TLSI
TLSI

Segment breakdown not available.

Related Comparisons